
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4447883/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nature Medicine, 2007, 13, 470-476.	30.7	446
2	HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO Journal, 2003, 22, 2729-2740.	7.8	382
3	MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (<i>Srebp2</i>) regulates HDL in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17321-17326.	7.1	346
4	Hepatitis C Virus Core Protein Inhibits Fas- and Tumor Necrosis Factor Alpha-Mediated Apoptosis via NF-κB Activation. Journal of Virology, 1999, 73, 4713-4720.	3.4	331
5	Inflammation-Associated Cancer Development in Digestive Organs: Mechanisms and Roles for Genetic and Epigenetic Modulation. Gastroenterology, 2012, 143, 550-563.	1.3	329
6	STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene, 2004, 23, 4921-4929.	5.9	282
7	TRANSMISSION OF HEPATITIS B VIRUS FROM HEPATITIS B CORE ANTIBODY-POSITIVE DONORS IN LIVING RELATED LIVER TRANSPLANTS. Transplantation, 1998, 65, 494-499.	1.0	257
8	Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology, 2000, 31, 488-495.	7.3	230
9	Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature, 2020, 577, 260-265.	27.8	168
10	Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID). Journal of Biological Chemistry, 2013, 288, 31715-31727.	3.4	140
11	Antibody to Hepatitis B Core Antigen and Risk for Hepatitis C–Related Hepatocellular Carcinoma. Annals of Internal Medicine, 2007, 146, 649.	3.9	130
12	Anti-viral protein APOBEC3G is induced by interferon- $\hat{l}\pm$ stimulation in human hepatocytes. Biochemical and Biophysical Research Communications, 2006, 341, 314-319.	2.1	127
13	Activation-Induced Cytidine Deaminase Links Between Inflammation and the Development of Colitis-Associated Colorectal Cancers. Gastroenterology, 2008, 135, 889-898.e3.	1.3	122
14	Accumulation of Somatic Mutations in TP53 in Gastric Epithelium WithÂHelicobacter pylori Infection. Gastroenterology, 2014, 147, 407-417.e3.	1.3	121
15	Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. International Journal of Cancer, 2007, 120, 469-476.	5.1	117
16	Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology, 2008, 47, 888-896.	7.3	116
17	Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. Journal of Gastroenterology, 2020, 55, 15-26.	5.1	115
18	Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing. PLoS ONE, 2011, 6, e24907.	2.5	86

HIROYUKI MARUSAWA

#	Article	IF	CITATIONS
19	Inflammationâ€mediated genomic instability: roles of activationâ€induced cytidine deaminase in carcinogenesis. Cancer Science, 2012, 103, 1201-1206.	3.9	83
20	Modelling mutational landscapes of human cancers in vitro. Scientific Reports, 2014, 4, 4482.	3.3	83
21	HBXIP, Cellular Target of Hepatitis B Virus Oncoprotein, Is a Regulator of Centrosome Dynamics and Cytokinesis. Cancer Research, 2006, 66, 9099-9107.	0.9	80
22	Organâ€specific profiles of genetic changes in cancers caused by activationâ€induced cytidine deaminase expression. International Journal of Cancer, 2008, 123, 2735-2740.	5.1	80
23	Mechanism for gastric cancer development by <i>Helicobacter pylori</i> infection. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1175-1181.	2.8	77
24	Dynamics of Hepatitis B Virus Quasispecies in Association with Nucleos(t)ide Analogue Treatment Determined by Ultra-Deep Sequencing. PLoS ONE, 2012, 7, e35052.	2.5	76
25	Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. Journal of Gastroenterology, 2017, 52, 26-38.	5.1	63
26	Up-regulation of Activation-Induced Cytidine Deaminase Causes Genetic Aberrations at the CDKN2b-CDKN2a in Gastric Cancer. Gastroenterology, 2010, 139, 1984-1994.	1.3	61
27	Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatology Research, 2018, 48, 597-607.	3.4	58
28	Inflammation and gastrointestinal cancer: An overview. Cancer Letters, 2014, 345, 153-156.	7.2	49
29	Host factors are important in determining clinical outcomes of Helicobacter pylori infection. Journal of Gastroenterology, 2006, 41, 1-9.	5.1	47
30	Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. Journal of Gastroenterology, 2012, 47, 444-451.	5.1	46
31	Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates β-catenin activity in a p53-dependent manner. Oncogene, 2004, 23, 7593-7600.	5.9	43
32	Proliferating EpCAM-Positive Ductal Cells in the Inflamed Liver Give Rise to Hepatocellular Carcinoma. Cancer Research, 2017, 77, 6131-6143.	0.9	41
33	Attenuation of proteolysisâ€mediated cyclin E regulation by alternatively spliced <i>Parkin</i> in human colorectal cancers. International Journal of Cancer, 2009, 125, 2029-2035.	5.1	40
34	Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver International, 2010, 30, 1241-1242.	3.9	39
35	Leptin Receptor Somatic Mutations Are Frequent in HCV-Infected Cirrhotic Liver and Associated With Hepatocellular Carcinoma. Gastroenterology, 2014, 146, 222-232.e35.	1.3	38
36	Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. International Journal of Cancer, 2012, 130, 1294-1301.	5.1	37

#	Article	IF	CITATIONS
37	<i>TERT</i> promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver diseaseâ€related hepatocellular carcinoma. International Journal of Cancer, 2016, 139, 2512-2518.	5.1	36
38	Role of a novel oncogenic protein, gankyrin, in hepatocyte proliferation. Journal of Gastroenterology, 2003, 38, 751-758.	5.1	35
39	The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers, 2021, 13, 2608.	3.7	34
40	Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis. Journal of Gastroenterology, 2019, 54, 628-640.	5.1	33
41	Helicobacter pylori-induced activation-induced cytidine deaminase expression and carcinogenesis. Current Opinion in Immunology, 2010, 22, 442-447.	5.5	32
42	Role of Activation-Induced Cytidine Deaminase in Inflammation-Associated Cancer Development. Advances in Immunology, 2011, 111, 109-141.	2.2	31
43	Aberrant AID expression and human cancer development. International Journal of Biochemistry and Cell Biology, 2008, 40, 1399-1402.	2.8	30
44	Long-term Prognosis and Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A Single-Center Experience. Transplantation Direct, 2017, 3, e334.	1.6	30
45	A novel mechanism for inflammation-associated carcinogenesis; an important role of activation-induced cytidine deaminase (AID) in mutation induction. Journal of Molecular Medicine, 2009, 87, 1023-1027.	3.9	29
46	Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen. Journal of Gastroenterology, 2001, 36, 633-636.	5.1	27
47	Expression of APOBEC2 is transcriptionally regulated by NF-κB in human hepatocytes. FEBS Letters, 2006, 580, 731-735.	2.8	27
48	Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma. Carcinogenesis, 2011, 32, 1706-1712.	2.8	25
49	Enhanced expression of activation-induced cytidine deaminase in human gastric mucosa infected by Helicobacter pylori and its decrease following eradication. Journal of Gastroenterology, 2014, 49, 427-435.	5.1	25
50	Helicobacter pylori-Mediated Genetic Instability and Gastric Carcinogenesis. Current Topics in Microbiology and Immunology, 2017, 400, 305-323.	1.1	25
51	Involvement of activation-induced cytidine deaminase in the development of colitis-associated colorectal cancers. Journal of Gastroenterology, 2011, 46, 6-10.	5.1	24
52	<i>MSH2</i> Dysregulation Is Triggered by Proinflammatory Cytokine Stimulation and Is Associated with Liver Cancer Development. Cancer Research, 2016, 76, 4383-4393.	0.9	23
53	Individualized Extension of Pegylated Interferon Plus Ribavirin Therapy for Recurrent Hepatitis C Genotype 1b After Living-Donor Liver Transplantation. Transplantation, 2010, 90, 661-665.	1.0	22
54	Clinical Characteristics of Non-B Non-C Hepatocellular Carcinoma: A Single-Center Retrospective Study. Digestion, 2011, 84, 43-49.	2.3	22

#	Article	IF	CITATIONS
55	Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence. Journal of Hepatology, 2014, 61, 492-501.	3.7	22
56	Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations. Cancer Research, 2015, 75, 3292-3301.	0.9	22
57	Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma. Cancers, 2019, 11, 405.	3.7	22
58	Mouse Models of Hepatitis B Virus Infection Comprising Host-Virus Immunologic Interactions. Pathogens, 2014, 3, 377-389.	2.8	21
59	Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c. Digestion, 2017, 96, 228-230.	2.3	21
60	Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Clinical Infectious Diseases, 2021, 73, e3349-e3354.	5.8	21
61	Regulation of Fasâ€Mediated Apoptosis by NFâ€îºB Activity in Human Hepatocyte Derived Cell Lines. Microbiology and Immunology, 2001, 45, 483-489.	1.4	20
62	Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. Scientific Reports, 2017, 7, 45605.	3.3	20
63	Genetic features of multicentric/multifocal intramucosal gastric carcinoma. International Journal of Cancer, 2018, 143, 1923-1934.	5.1	20
64	Limited Benefit of Biochemical Response to Combination Therapy for Patients With Recurrent Hepatitis C After Living-Donor Liver Transplantation. Transplantation, 2008, 85, 855-862.	1.0	18
65	Molecular Pathogenesis of Helicobacter pylori-Related Gastric Cancer. Gastroenterology Clinics of North America, 2015, 44, 625-638.	2.2	17
66	Realâ€world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1â€and 2â€infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Journal of Medical Virology, 2021, 93, 6247-6256.	5.0	16
67	Multiregional wholeâ€genome sequencing of hepatocellular carcinoma with noduleâ€inâ€nodule appearance reveals stepwise cancer evolution. Journal of Pathology, 2020, 252, 398-410.	4.5	15
68	Expansion of viral variants associated with immune escape and impaired virion secretion in patients with HBV reactivation after resolved infection. Scientific Reports, 2018, 8, 18070.	3.3	14
69	Survey of Hepatitis B Virus Co-infection in Hepatitis C Virus-infected Patients Suffering from Chronic Hepatitis and Hepatocellular Carcinoma in Japan. Japanese Journal of Cancer Research, 1999, 90, 1270-1272.	1.7	13
70	Lens culinaris agglutinin-A-reactive alpha-fetoprotein as a marker for liver atrophy in fulminant hepatic failure. Hepatology Research, 2003, 26, 98-105.	3.4	13
71	The RNA-editing Enzyme APOBEC1 Requires Heterogeneous Nuclear Ribonucleoprotein Q Isoform 6 for Efficient Interaction with Interleukin-8 mRNA. Journal of Biological Chemistry, 2014, 289, 26226-26238.	3.4	12
72	A model of liver carcinogenesis originating from hepatic progenitor cells with accumulation of genetic alterations. International Journal of Cancer, 2014, 134, 1067-1076.	5.1	12

#	Article	IF	CITATIONS
73	Hepatic inflammation facilitates transcription-associated mutagenesis via AID activity and enhances liver tumorigenesis. Carcinogenesis, 2015, 36, 904-913.	2.8	12
74	Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatology Research, 2016, 46, 541-551.	3.4	12
75	<i>Hes1</i> Is Essential in Proliferating Ductal Cell–Mediated Development of Intrahepatic Cholangiocarcinoma. Cancer Research, 2020, 80, 5305-5316.	0.9	11
76	Chronic Rejection Associated with Antiviral Therapy for Recurrent Hepatitis C after Living-Donor Liver Transplantation. Transplantation, 2014, 97, 344-350.	1.0	10
77	Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. JHEP Reports, 2020, 2, 100138.	4.9	10
78	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatology Communications, 2022, 6, 461-472.	4.3	10
79	Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. Scientific Reports, 2020, 10, 13021.	3.3	8
80	Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. Cancers, 2015, 7, 1037-1051.	3.7	7
81	Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B. PLoS ONE, 2017, 12, e0185442.	2.5	7
82	DNA methyltransferase 3B plays a protective role against hepatocarcinogenesis caused by chronic inflammation via maintaining mitochondrial homeostasis. Scientific Reports, 2020, 10, 21268.	3.3	7
83	Genetic Landscape of Multistep Hepatocarcinogenesis. Cancers, 2022, 14, 568.	3.7	7
84	Expansion of Gastric Intestinal Metaplasia with Copy Number Aberrations Contributes to Field Cancerization. Cancer Research, 2022, 82, 1712-1723.	0.9	7
85	Landscape of Genetic Aberrations Detected in Human Colorectal Cancers. Gastroenterology, 2013, 145, 686-688.	1.3	6
86	Association of Macâ€2â€binding protein glycosylation isomer level with nutritional status in chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1649-1658.	2.8	6
87	Comparative proteomics of <i>Helicobacter pylori</i> strains reveals geographical features rather than genomic variations. Genes To Cells, 2019, 24, 139-150.	1.2	6
88	Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus. Carcinogenesis, 2021, 42, 672-684.	2.8	6
89	Pneumothorax Following Esophageal Perforation Due to Ingested Fish Bone. Clinical Gastroenterology and Hepatology, 2010, 8, A24.	4.4	5
90	Genetic Pathogenesis of Inflammation-Associated Cancers in Digestive Organs. Pathogens, 2021, 10, 453.	2.8	5

#	Article	IF	CITATIONS
91	Acquisition of Genetic Aberrations by Activation-Induced Cytidine Deaminase (AID) during Inflammation-Associated Carcinogenesis. Cancers, 2011, 3, 2750-2766.	3.7	4
92	Characteristics of Hepatocellular Carcinoma With Stem/Progenitor Cell Phenotypes. Gastroenterology, 2014, 146, 579-581.	1.3	4
93	Activation of TNF-α-AID axis and co-inhibitory signals in coordination with Th1-type immunity in a mouse model recapitulating hepatitis B. Antiviral Research, 2017, 139, 138-145.	4.1	4
94	Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication. Pathogens, 2022, 11, 430.	2.8	4
95	How can we prevent viral reactivation in liver transplantation from donors with latent hepatitis B virus infection?. Journal of Gastroenterology, 2001, 36, 212-213.	5.1	3
96	Acute Epstein–Barr virus infection presenting as severe gastroenteritis without infectious mononucleosis-like manifestations. Clinical Journal of Gastroenterology, 2009, 2, 398-403.	0.8	3
97	A Marker for Dormant Cancer Stem Cells in Human Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1353-1355.	1.3	3
98	Novel Mouse Models of Hepatocarcinogenesis with Stepwise Accumulation of Genetic Alterations. Digestive Diseases, 2013, 31, 454-458.	1.9	3
99	Ultrasoundâ€guided microfoam sclerotherapy with polidocanol for symptomatic giant hepatic cyst: Initial experience. Hepatology Research, 2018, 48, 1055-1063.	3.4	3
100	Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis. Internal Medicine, 2019, 58, 67-71.	0.7	3
101	Comprehensive characterization of hepatitis B virus-associated multifocal hepatocellular carcinoma using a multi-omics strategy. Annals of Translational Medicine, 2015, 3, 3.	1.7	3
102	Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing. Scientific Reports, 2022, 12, 7083.	3.3	3
103	Effective treatment for <i>de novo</i> hepatitis B with nucleotide analogue in patients with hematological malignancies. American Journal of Hematology, 2009, 84, 315-316.	4.1	2
104	Large-Scale Identification of Effector Genes That Mediate the Type I Interferon Antiviral Response. Gastroenterology, 2012, 142, 178-180.	1.3	2
105	Two cases of granulomatous hepatitis due to disseminated bacillus Calmette-Guérin (BCC) disease. Acta Hepatologica Japonica, 2017, 58, 406-414.	0.1	2
106	Small Bowel Bleeding Caused by Myeloid Sarcoma. Internal Medicine, 2022, 61, 123-124.	0.7	2
107	Spontaneous Rupture of Intrahepatic Aneurysm. Clinical Gastroenterology and Hepatology, 2007, 5, A30.	4.4	1
108	<i>De novo</i> hepatitis B virus infection in hepatocellular carcinoma following eradication of hepatitis C virus by interferon therapy. Hepatology Research, 2010, 40, 661-665.	3.4	1

HIROYUKI MARUSAWA

#	Article	IF	CITATIONS
109	Recurrent Somatic Mutations in Human Gastric Cancers Identified by Whole Exome Sequencing. Gastroenterology, 2012, 143, 1385-1387.	1.3	1
110	Pretransplant Serum Hepatitis C Virus RNA Levels Predict Response to Antiviral Treatment after Living Donor Liver Transplantation. PLoS ONE, 2013, 8, e58380.	2.5	1
111	Aberrant AID Expression by Pathogen Infection. , 2015, , 389-397.		1
112	Tu1667 RNA-Seq Analysis of Innate Immune Response in Hepatitis B. Gastroenterology, 2016, 150, S1162.	1.3	0
113	Tu1666 Profiling of Acquired Immune Response Against Hepatitis B Virus Infection Determined By Direct Digital Counting System. Gastroenterology, 2016, 150, S1162.	1.3	Ο
114	Evolving Immunotherapy Approaches for Hepatocellular Carcinoma. Current Human Cell Research and Applications, 2018, , 93-110.	0.1	0
115	Stepwise generation of AID knock-in and conditional knockout mice from a single gene-targeting event. International Immunology, 2021, 33, 387-398.	4.0	Ο
116	Detection of activation-induced cytidine deaminase in gastric epithelial cells infected with cag pathogenicity island-positive Helicobacter pylori. Protocol Exchange, 0, , .	0.3	0
117	Association between Body Mass Index and Diabetes and Hepatocellular Carcinoma. Annals of Internal Medicine, 2008, 148, 167.	3.9	Ο
118	Molecular mechanism of colitis-associated colorectal carcinogenesis. Inflammation and Regeneration, 2012, 32, 067-071.	3.7	0
119	Abstract 5366: Mutation signature of TP53 gene in H. pylori-associated inflamed gastric mucosa during gastric carcinogenesis. , 2014, , .		0
120	The efficacy and safety of lenvatinib in patients with intermediate-stage hepatocellular carcinoma: A nationwide multicenter study in Japan Journal of Clinical Oncology, 2020, 38, 548-548.	1.6	0